Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

Also called NCT01398592

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 187 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01398592
  • EudraCT 2011-000518-21
Other papers using this trial's data
  • Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial Diabetes & metabolism, 2015-06 DOI, PubMed 25457473

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01398592. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
Acronym
FPG-VISIT
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Sitagliptin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01398592
Content hash
9cf0600b2c3b60c584ad86509978f5ee0f9f444d06d3007f947e95dd51371b74